Vital KSK Holdings, Inc. (TYO:3151)
Japan · Delayed Price · Currency is JPY 1,238.00
-1.00 (-0.08%)
Jul 25, 2025, 3:30 PM JST
Vital KSK Holdings Revenue
In the fiscal year ending March 31, 2025, Vital KSK Holdings had annual revenue of 600.37B JPY with 2.19% growth. Vital KSK Holdings had revenue of 139.69B in the quarter ending March 31, 2025, with 0.81% growth.
Revenue
600.37B
Revenue Growth
+2.19%
P/S Ratio
0.10
Revenue / Employee
159.84M
Employees
3,756
Market Cap
59.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 600.37B | 12.89B | 2.19% |
| Mar 31, 2024 | 587.48B | 7.71B | 1.33% |
| Mar 31, 2023 | 579.77B | 2.52B | 0.44% |
| Mar 31, 2022 | 577.25B | 40.22B | 7.49% |
| Mar 31, 2021 | 537.03B | -25.48B | -4.53% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,196.22B |
| Takeda Pharmaceutical Company | 4,581.55B |
| Daiichi Sankyo Company | 1,886.26B |
| HOYA Corporation | 866.03B |
| Terumo | 1,036.17B |
| Otsuka Holdings | 2,393.18B |
| Astellas Pharma | 1,912.32B |
| Shionogi & | 438.27B |